The Dermatological Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: January 2016
Number of Pages: 187
Number of Tables and Figures: 46

Synopsis: With an aging world population and rising expectations about skin, hair, and nail appearance, the prevalence of some of the most common skin disorders continues to rise. With the exception of Melanoma, most skin disorders are not life threatening. However, they can have serious effects on daily life by causing visible physical damage, embarrassment, and social and occupational restrictions.

Although surgery and other therapies are widely used for the treatment of certain skin conditions, dermatological drugs continue to account for the highest percentage of spending within the wider market for dermatological products. Expected to reach nearly $23 Billion in global spending by the end of 2016, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.

The “Dermatological Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline,  opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2016 through to 2030. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.


For a sample of the report or any further inquiries please contact info@snstelecom.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500


Key Findings:
The report has the following key findings:
  • Expected to reach nearly $23 Billion in global spending by the end of 2016, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis.
  • The distinction between skin diseases and cosmetic dermatological problems is diminishing with people’s rising expectations about skin, hair, and nail appearance.
  • Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.
  • New dermatology R&D programs are focused on monoclonal antibodies, JAK inhibitors, MEK inhibitors and PDE4 inhibitors, among other therapies.
  • The industry continues to witness consolidation in the form of both acquisitions and mergers.

Topics Covered:
The report covers the following topics:
  • Dermatological drugs ecosystem
  • Market drivers and barriers
  • Dermatological disorders, application areas and key trends
  • Analysis of key drug classes and leading dermatological drugs
  • Future drug development pipeline
  • Dermatological drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of over 70 leading ecosystem players, including dermatological drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2016 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Category
    • Acne & Rosacea
    • Alopecia & Hair Disorders
    • Dermatitis
    • Psoriasis
    • Skin Infections
    • Skin Cancer
    • Other Conditions
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the dermatological drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in dermatology?
  • How big is the market for Psoriasis drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should dermatological drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AB Science
Abbot Laboratories
AbbVie
AbGenomics International
Aclaris Therapeutics
Actavis
Actelion Pharmaceuticals
Alder Biopharmaceuticals
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
ApoPharma
Apotex
Array BioPharma
Astellas Pharma
AstraZeneca
Bayer
BioAlliance Pharma
Biofrontera Group
Biotest
Birken
BMS (Bristol-Myers Squibb)
Boehringer-Ingelheim
Can-Fite BioPharma
Celgene Corporation
Cellceutix Corporation
Chugai Pharmaceuticals
Cipher Pharmaceuticals
Creabilis
Cubist Pharmaceuticals
Depomed
Dermira
Dr. Reddy's Laboratories
Eli Lilly and Company
Exelixis
FDA (Food and Drug Administration)
Forward-Pharma
G&E Corporation (G&E Herbal Biotechnology)
Galderma
Genentech
GSK (GlaxoSmithKline)
Hospira
Idera Pharmaceuticals
Immune Pharmaceuticals
Incyte Corporation
Janssen Biotech
Johnson & Johnson
JT (Japan Tobacco)
Kadmon Corporation
Kythera Biopharmaceuticals
LEO Pharma
Maruho
Mayne Pharma Group
Meda Pharmaceuticals
Melinta Therapeutics
Merck & Co.
Merck KGaA
Moleculin Biotech
MorphoSys
Mylan
Nestle Skin Health
Novan Therapeutics
Novartis
Onxeo
Pfizer
Pharmacyclics
PharmaDerm
Photocure
Pierre Fabre (Laboratoires Pierre Fabre)
Poli Group
Polichem
Promius Pharma
Provectus Biopharmaceuticals
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Sandoz
Sanofi
Sinclair Pharma
Stiefel Laboratories
Sun Pharma (Sun Pharmaceutical Industries)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The Medicines Company
Topica Pharmaceuticals
Topotarget
Torii Pharmaceutical Company
Tribute Pharmaceuticals
UCB
University of Pennsylvania
Valeant Pharmaceuticals
VBL Therapeutics
XenoPort

Comments